GlassScriptPhysician profile
Bing Xie Behrens
NPI 1841256609
$5,301.71
in general payments reported to CMS, 2019-2025
23 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $204 · 2021: $375 · 2022: $702 · 2023: $737 · 2024: $2,032 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510 · Travel and Lodging: $853 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.64 |
| Travel and Lodging | $853.11 |
| Education | $254.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,456.84 | 2019-2025 | Inspire |
| Abbvie INC. | $974.73 | 2022-2025 | Botox, Ubrelvy |
| Harmony Biosciences LLC | $532.68 | 2023-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $450.87 | 2020-2025 | |
| Amgen INC. | $383.00 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $370.92 | 2022-2025 | |
| Emd Serono, INC. | $178.38 | 2022-2023 | Mavenclad |
| Axsome Therapeutics, INC. | $168.98 | 2023-2025 | Sunosi |
| Allergan, INC. | $156.86 | 2020-2021 | |
| Eisai INC. | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $91.00 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $81.71 | 2024 | Quviviq |
| Fisher & Paykel Healthcare INC | $59.77 | 2024-2025 | Fisher & Paykel Healthcare |
| Resmed Corp | $58.93 | 2024-2025 | |
| Biogen, INC. | $52.00 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $22.27 | 2020 | |
| Amneal Pharmaceuticals LLC | $21.79 | 2023 | Rytary |
| Zoll Respicardia, INC. | $21.68 | 2023 | Remede System |
| Avadel Cns Pharmaceuticals, LLC | $20.43 | 2025 | Lumryz |
| Philips North America LLC | $20.01 | 2022 | |
| Horizon Therapeutics Plc | $19.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.12 | 2022 | |
| Lilly USA, LLC | $15.98 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bing Behrens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.